Dr. Ana   Oton
My Social Links

Dr. Ana Oton

Research Scientist
Eli Lilly and Company, USA


Highest Degree
PostDoc Fellow in Hematology from University of Pittsburgh School of Medicine, USA

Share this Profile

Area of Interest:

Medicine
100%
Hematology
62%
Oncology
90%
Metabolism
75%
Cancer
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Hess, L.M., Z.L. Cui, X.I. Li, A.B. Oton, S. Shortenhaus and I.A. Watson, 2018. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States. J. Med. Econ., (In Press). 10.1080/13696998.2018.1467918.
    CrossRef  |  Direct Link  |  
  2. Langer, C.J., L.G. Paz-Ares, A.J. Wozniak, C. Gridelli and F. de Marinis et al., 2017. Safety analyses of pemetrexed-cisplatin and pemetrexed maintenance therapies in patients with advanced non-squamous NSCLC: Retrospective analyses from 2 phase III studies. Clin. Lung Cancer, 18: 489-496.
    CrossRef  |  Direct Link  |  
  3. Hess, L.M., Z.L. Cui, Y. Wu, Y. Fang, P.J. Gaynor and A.B. Oton, 2017. Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040. J. Med. Econ., 20: 850-862.
    CrossRef  |  Direct Link  |  
  4. Hess, L.M., D.M. Kern, G.C. Carter, K. Winfree, L. Wang, A. Sontag and A.B. Oton, 2017. Real-world treatment sequences and outcomes among patients with non-small cell lung cancer (RESOUNDS) in the United States: Study protocol. JMIR Res. Protocols, Vol. 6, No. 10. 10.2196/resprot.7750.
    CrossRef  |  Direct Link  |  
  5. Hess, L.M., A. Louder, K. Winfree, Y.E. Zhu, A.B. Oton and R. Nair, 2017. Factors associated with adherence to and treatment duration of erlotinib among patients with non-small cell lung cancer. J. Managed Care Specialty Pharm., 23: 643-652.
    CrossRef  |  Direct Link  |  
  6. Rolfo, C., C. Caglevic, D. Bretel, D. Hong and L.E. Raez et al., 2016. Cancer clinical research in Latin America: Current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open, Vol. 1, No. 4. 10.1136/esmoopen-2016-000055.
    CrossRef  |  Direct Link  |  
  7. Lopez-Chavez, A., A. Thomas, M.O. Evbuomwan, L. Xi and G. Chun et al., 2016. EGFR mutations in Latinos from the United States and Latin America. J. Global Oncol., 2: 259-267.
    CrossRef  |  Direct Link  |  
  8. Weickhardt, A.J., R.C. Doebele, W.T. Purcell, P.A. Bunn and A.B. Oton et al., 2013. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer, 119: 2383-2390.
    CrossRef  |  Direct Link  |  
  9. Weickhardt, A.J., M.S. Rothman, S. Salian-Mehta, K. Kiseljak-Vassiliades and A.B. Oton et al., 2012. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer, 118: 5302-5309.
    CrossRef  |  Direct Link  |  
  10. Doebele, R.C., X. Lu, C. Sumey, D.A. Maxson and A.J. Weickhardt et al., 2012. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer, 118: 4502-4511.
    CrossRef  |  Direct Link  |  
  11. Camidge, D.R., S.A. Kono, X. Lu, S. Okuyama and A.E. Baron et al., 2011. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thoracic Oncol., 6: 774-780.
    CrossRef  |  Direct Link  |  
  12. Doebele, R.C., A.B. Oton, N. Peled, D.R. Camidge and P.A. Bunn Jr., 2010. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer, 69: 1-12.
    CrossRef  |  Direct Link  |  
  13. Calverley, D.C., T.L. Phang, Q.G. Choudhury, B. Gao, A.B. Oton, M.J. Weyant and M.W. Geraci, 2010. Significant downregulation of platelet gene expression in metastatic lung cancer. Clin. Transl. Sci., 3: 227-232.
    CrossRef  |  Direct Link  |  
  14. Peled, N., A.B. Oton, F.R. Hirsch and P. Bunn, 2009. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy, 1: 19-25.
    CrossRef  |  Direct Link  |  
  15. Oton, A.B., H. Wang, X. Leleu, M.F. Melhem and D. George et al., 2008. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leukemia Lymphoma, 49: 1738-1744.
    CrossRef  |  Direct Link  |  
  16. Alsayed, Y., X. Leleu, A. Leontovich, A.B. Oton, M. Melhem, D. George and I.M. Ghobrial, 2008. Proteomics analysis in post-transplant lymphoproliferative disorders. Eur. J. Haematol., 81: 298-303.
    CrossRef  |  Direct Link  |  
  17. Owonikoko, T.K., C.C. Ragin, C.P. Belani, A.B. Oton, W.E. Gooding, E. Taioli and S.S. Ramalingam, 2007. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology and end results database. J. Clin. Oncol., 25: 5570-5577.
    CrossRef  |  PubMed  |  Direct Link  |